Last updated: July 25, 2026
Journey Medical Corporation v. Teva Pharmaceuticals, Inc. (D. Idaho 1:22-cv-00288): Litigation Summary, Claims at Issue, and Expected Generic Exposure
Executive summary: The docket 1:22-cv-00288 reflects patent enforcement litigation by Journey Medical Corporation against Teva Pharmaceuticals, Inc. The filing date places the case in the Paragraph IV-era Orange Book challenge window, but the record details that govern a true merits-and-claims analysis (asserted patent numbers, claim construction rulings, F/R/D dates, and settlement or injunction terms) are not present in the material provided here. Without those case-specific identifiers and operative filings, a complete and accurate litigation summary and strength analysis cannot be produced.
What is Journey Medical Corporation v. Teva Pharmaceuticals, Inc. case 1:22-cv-00288 about?
Answer: A patent dispute in the federal court docket 1:22-cv-00288, filed in 2022, brought by Journey Medical Corporation against Teva Pharmaceuticals, Inc. The precise asserted patents, counts for relief, and accused product(s) are not included in the available inputs, so the nature of infringement contentions cannot be stated precisely.
What patents does Journey assert in 1:22-cv-00288?
No asserted patent identifiers (publication numbers, U.S. patent numbers, or Orange Book listing IDs) are available in the provided information. Without patent numbers, claim coverage and expiration timing cannot be mapped.
What Teva product is accused?
No accused product name, strength, dosage form, or ANDA/BLA reference is included. Without the product identity, infringement analysis by dosage form and formulation cannot be performed.
What claims are pleaded (infringement, declaratory judgment, injunction)?
The pleaded causes of action and requested relief are not provided. Without the complaint and operative amendments, the litigation posture cannot be characterized.
Which court is handling 1:22-cv-00288 and what procedural posture matters most?
Answer: The case is docketed as 1:22-cv-00288. The procedural posture key to generic launch risk includes: whether the court issued an early case management order, conducted claim construction, entered an infringement/validity decision, or held a trial; and whether a settlement triggered a designed launch date.
No procedural milestones (e.g., Rule 16 schedule, Markman date, summary judgment rulings, trial dates, judgment or dismissal order) are available in the inputs.
Is there claim construction (Markman) or summary judgment?
Not available.
Has the court issued any dispositive ruling affecting validity or infringement?
Not available.
Is there an injunction, consent decree, or modified launch agreement?
Not available.
What does the litigation timeline imply for Teva’s generic launch risk?
Answer: Filing in 2022 places the dispute within the standard post-ANDA litigation window, where key risk drivers are: the asserted patent’s expiration, any PTE or FDA exclusivity effects, and whether the case progressed to a merits decision before a “designated” launch date.
However, a litigation-to-launch analysis requires the asserted patent expiration dates, regulatory approval timeline, and any settlement terms. None are present here.
When does the asserted patent estate expire and how does that align with ANDA approval?
Not available.
What are typical decision gates that control launch timing here?
Not available.
How strong is Journey’s asserted patent estate in this case?
Answer: Patent strength depends on the asserted claim scope, the novelty and nonobviousness profile, the prosecution history, prior art landscape, and any prior validity outcomes. The inputs do not include the asserted patent claims, priority dates, or prosecution/validity arguments.
A “strong/weak” rating cannot be computed without:
- the exact patent numbers and independent claim language,
- the invalidity theories raised by Teva (anticipation, obviousness, written description, indefiniteness, prosecution history estoppel),
- and any court rulings.
What patent issues are most likely argued in Journey v. Teva (validity, infringement, written description)?
Answer: Typical arguments in ANDA-driven patent cases include anticipation/obviousness, lack of enablement/written description, indefiniteness, and noninfringement based on formulation differences or process changes. But this case-specific issue map cannot be produced without the complaint, answers, invalidity contentions, claim charts, or court orders.
Are the disputes centered on formulation, manufacturing, or method-of-use?
Not available.
Are there any design-arounds or carve-outs discussed in the pleadings?
Not available.
What settlements or consent judgments exist for 1:22-cv-00288, and how do they affect Teva’s entry?
Answer: Settlement terms drive commercial timing, including:
- permitted launch date,
- royalty or license structure,
- carve-outs from design-around,
- dismissal with prejudice of certain claims.
No settlement or consent judgment details are included.
What is the Orange Book status of the relevant product in this litigation?
Answer: Orange Book status requires identifying the drug product at issue and listing the patents that appear for that NDA/AND A reference. The inputs do not include the drug name, NDC, or Orange Book patent list.
Without that, this section cannot be completed.
How does this case compare with other Journey Medical Corporation vs. generic company patent litigations?
Answer: Comparative analysis requires:
- the asserted patent families,
- the generic challengers,
- the outcomes (dismissal, summary judgment, trial verdicts),
- and the settlement patterns.
No comparative docket list or prior cases are provided.
What generic entry risks exist for Teva and competitors if Journey’s case fails or succeeds?
Answer: Entry risk is dominated by:
- whether the court finds invalidity or noninfringement,
- whether any remaining patents block entry,
- and whether the settlement allows market entry under license terms.
This case-specific risk cannot be quantified without outcomes or settlement structure.
Key Takeaways
- 1:22-cv-00288 is a Journey Medical Corporation v. Teva Pharmaceuticals, Inc. patent litigation docket filed in 2022.
- A complete, accurate litigation summary and analysis cannot be produced from the information provided because the operative case record is missing key fields: asserted patent numbers, accused product/drug, procedural milestones, rulings, and settlement terms.
- Generic launch exposure and Orange Book mapping are not possible without identifying the Orange Book-listed patents and the specific drug product implicated by the complaint.
FAQs
- What does an ANDA Paragraph IV filing imply for patent litigation like 1:22-cv-00288?
- How do claim construction outcomes typically influence infringement findings in method-of-use vs. formulation disputes?
- What court milestones most strongly predict whether a generic launch will be enjoined in Hatch-Waxman cases?
- How are Orange Book patent lists used to determine which patents can be asserted in an infringement suit?
- What factors determine whether a settlement permits early launch without final merits adjudication?
References (APA)
- No sources were provided with the request content sufficient to cite the docket record, complaint, or orders for 1:22-cv-00288.
